Amneal Pharmaceuticals
AMRX
144 hedge funds and large institutions have $430M invested in Amneal Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 54 increasing their positions, 32 reducing their positions, and 15 closing their positions.
8,250% more call options, than puts
Call options by funds: $668K | Put options by funds: $8K
113% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 15
69% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 32
42% more capital invested
Capital invested by funds: $302M → $430M (+$128M)
13% more funds holding
Funds holding: 128 → 144 (+16)
2.52% more ownership
Funds ownership: 63.56% → 66.08% (+2.5%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$5.57M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$5.31M |
| 3 |
Nuveen
Charlotte,
North Carolina
|
+$3.18M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$2.9M |
| 5 |
Russell Investments Group
London,
United Kingdom
|
+$2.77M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EP
Eversept Partners
New York
|
-$9.77M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
-$4.54M |
| 3 |
Allspring Global Investments
Charlotte,
North Carolina
|
-$1.27M |
| 4 |
Millennium Management
New York
|
-$1.11M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$862K |
AMRX Hedge Fund Activity: Q3 2023 in Review
144 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Amneal Pharmaceuticals (AMRX) for Q3 2023, worth a combined $430M — up 42% from $302M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new AMRX positions and 15 closed out — a net gain of 17 holders — while 54 added to existing stakes and 32 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $5.57M. The largest seller was Eversept Partners, cutting an estimated $9.77M.
- 144 institutional investors held Amneal Pharmaceuticals (AMRX) as of Q3 2023, up from 128 in Q2 2023.
- Funds reported $430M of Amneal Pharmaceuticals stock for Q3 2023, up 42% quarter-over-quarter.
- 32 funds opened new Amneal Pharmaceuticals positions in Q3 2023 and 15 closed out, a net change of +17 holders.
- The largest Amneal Pharmaceuticals buyer in Q3 2023 was Citadel Advisors, an estimated $5.57M added.
- The largest Amneal Pharmaceuticals seller in Q3 2023 was Eversept Partners, an estimated $9.77M sold.
Based on aggregated 13F filings for Q3 2023.